Wednesday, June 19, 2013 Last update: 8:40 AM
Company Tech News as it Breaks
Cadence Pharmaceuticals, Inc.
News articles for Cadence Pharmaceuticals, Inc.:
Wednesday, May 8, 2013
- Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013SAN DIEGO, May 8, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's management will present a corporate overview at the following investment conferences during the month of ... read more
Thursday, May 2, 2013
- Cadence Pharmaceuticals Reports First Quarter 2013 Financial ResultsSAN DIEGO, May 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2013. During the first quarter of 2013, Cadence reported ... read more
Thursday, April 25, 2013
- Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013SAN DIEGO, April 25, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its first quarter ended March 31, 2013 financial results on ... read more
Thursday, March 14, 2013
- Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of DirectorsSAN DIEGO, March 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Stephen L. Newman, M.D., to the company's board of directors. "We are ... read more
Tuesday, March 12, 2013
- Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National FormularySAN DIEGO, March 12, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), announced today that the Department of Veterans Affairs has made OFIRMEV(®) (acetaminophen) injection available on the VA National Formulary (VANF). The VANF is a list of products (drugs and supplies) generally covered under VA pharmacy ... read more
Thursday, March 7, 2013
- Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial ResultsSAN DIEGO, March 7, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the fourth quarter and full year ended December 31, 2012. For the fourth quarter of ... read more
Wednesday, March 6, 2013
- Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) InjectionSAN DIEGO, March 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply ... read more
Thursday, February 28, 2013
- Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2012 ... read more
Tuesday, February 26, 2013
- Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview ... read more
Wednesday, February 6, 2013
- Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview ... read more
Wednesday, January 23, 2013
- Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue GuidanceSAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a preliminary (unaudited) estimate of net product revenue from sales of OFIRMEV(®) (acetaminophen) injection ... read more